Inflammatory Breast Disease - Pipeline Insight, 2024

This “Inflammatory-Breast-Disease- Pipeline Insight, 2024” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Inflammatory-Breast-Disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Inflammatory-Breast-Disease: Understanding

Inflammatory-Breast-Disease: Overview

Inflammatory breast cancer (IBC) is rare and accounts for only 1% to 5% of all breast cancers. Although it is a type of invasive ductal carcinoma, its symptoms, outlook, and treatment are different. IBC causes symptoms of breast inflammation like swelling and redness, which is caused by cancer cells blocking lymph vessels in the skin causing the breast to look inflamed. Inflammatory breast cancer (IBC) causes a number of signs and symptoms, most of which develop quickly (within 3-6 months), including: Swelling (edema) of the skin of the breast, redness involving more than one-third of the breast, pitting or thickening of the skin of the breast so that it may look and feel like an orange peel, a retracted or inverted nipple, one breast looking larger than the other because of swelling, one breast feeling warmer and heavier than the other or a breast that may be tender, painful or itchy. If inflammatory breast cancer (IBC) is suspected, one or more of the following imaging tests may be done: Mammogram, breast ultrasound, breast MRI (magnetic resonance imaging) scan. Often a photo of the breast is taken to help record the amount of redness and swelling before starting treatment. Inflammatory breast cancer is diagnosed by a biopsy, taking out a small piece of the breast tissue and looking at it in the lab. This might mean a punch biopsy of the breast skin that is abnormal. The cancer cells in the biopsy will be examined in the lab to determine their grade. Women whose breast cancer cells have hormone receptors are likely to benefit from treatment with hormone therapy drugs. Cancer cells that make too much of a protein called HER2 or too many copies of the gene for that protein may be treated by certain drugs that target HER2. In certain cases, other gene mutations (changes) or proteins might be tested for to see if specific drugs might be helpful. Inflammatory breast cancer (IBC) is considered an aggressive cancer because it grows quickly, is more likely to have spread at the time it’s found, and is more likely to come back after treatment than other types of breast cancer. The outlook is generally not as good as it is for other types of breast cancer. Survival rates can give an idea of what percentage of people with the same type and stage of cancer are still alive a certain amount of time (usually 5 years) after they were diagnosed. Inflammatory breast cancer (IBC) that has not spread outside the breast is stage III. In most cases, treatment is chemotherapy first to try to shrink the tumor, followed by surgery to remove the cancer. Radiation and often other treatments, like more chemotherapy or targeted drug therapy, are given after surgery. Because IBC is so aggressive, breast conserving surgery (lumpectomy) and sentinel lymph node biopsy are typically not part of the treatment. IBC that has spread to other parts of the body (stage IV) may be treated with chemotherapy, hormone therapy, and/or targeted drugs.

Inflammatory-Breast-Disease- Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Inflammatory-Breast-Disease pipeline landscape is provided which includes the disease overview and Inflammatory-Breast-Disease treatment guidelines. The assessment part of the report embraces, in depth Inflammatory-Breast-Disease commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Inflammatory-Breast-Disease collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Inflammatory-Breast-Disease R&D. The therapies under development are focused on novel approaches to treat/improve Inflammatory-Breast-Disease.

Inflammatory-Breast-Disease Emerging Drugs Chapters

This segment of the Inflammatory-Breast-Disease report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Inflammatory-Breast-Disease Emerging Drugs

Ruxolitinib: Incyte Corporation Opzelura, a novel cream formulation of Incyte’s selective JAK1/JAK2 inhibitor ruxolitinib, is the first and only topical JAK inhibitor approved for use in the United States for the topical short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis (AD) in non-immunocompromised patients 12 years of age and older whose disease is not adequately controlled with topical prescription therapies, or when those therapies are not advisable. Use of Opzelura in combination with therapeutic biologics, other JAK inhibitors, or potent immunosuppressants, such as azathioprine or cyclosporine, is not recommended. Additionally, ruxolitinib cream is in Phase III development for the treatment of adolescents and adults with vitiligo in the TRuE-V clinical program. Currently, the drug is in Phase II stage of Clinical trial evaluation for the treatment ofIBC.

Panitumumab: Amgen Vectibix (panitumumab), is the first fully human monoclonal anti-EGFR antibody approved by the FDA for the treatment of m CRC. Vectibix was approved in the U.S. in September 2006 as a monotherapy for the treatment of patients with EGFR-expressing m CRC after disease progression after prior treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy. Panitumumab treatment converts the immunosuppressive IBC TME to an immunoreactive status by modulating the global expression of chemokines by downregulating the EGR1 transcription factor. This modulation of the TME by panitumumab improves the inhibition of IBC tumor growth by an ICI. Currently, the drug is in Phase II stage of Clinical trial evaluation for thetreatmentofIBC.

Inflammatory-Breast-Disease: Therapeutic Assessment

This segment of the report provides insights about the different Inflammatory-Breast-Disease drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Inflammatory-Breast-Disease

There are approx. 5+ key companies which are developing the therapies for Inflammatory-Breast-Disease. The companies which have their Inflammatory-Breast-Disease drug candidates in the most advanced stage, i.e. phase II include, Incyte Corporation.

Phases

This report covers around 5+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Inflammatory-Breast-Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

Molecule Type

Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Inflammatory-Breast-Disease: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Inflammatory-Breast-Disease therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Inflammatory-Breast-Disease drugs.

Inflammatory-Breast-Disease Report Insights

• Inflammatory-Breast-Disease Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Inflammatory-Breast-Disease Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Inflammatory-Breast-Disease drugs?
• How many Inflammatory-Breast-Disease drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Inflammatory-Breast-Disease?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Inflammatory-Breast-Disease therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Inflammatory-Breast-Disease and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Incyte Corporation
• Amgen

Key Products

• Ruxolitinib
• Panitumumab